Neurologists and researchers with the University of Miami Health System are evaluating a drug that may have the potential to protect against, slow down, and possibly, eventually improve the memory and thinking challenges assocated with Alzheimer’s disease.
Participants are currently being screened for the new national Alzheimer’s disease (AD) phase 2 clinical study, called T2 Protect AD. Researchers are evaluating a drug called Troriluzole, which modulates glutamate, thereby protecting against neuron loss. Glutamate problems in the brain can lead to brain cell dysfunction and disease, including Alzheimer’s disease.
“We are hoping this drug truly makes a difference in slowing progression of this illness,” said Dr. Bernard S. Baumel, interim chief of the Cognitive Disorders Division at the University of Miami Miller School of Medicine, and director of memory disorders clinical trials. “It’s a unique compound that takes a different approach than most recent drugs. Riluzole has shown efficacy in ALS patients, and the prodrug now offers the possibility of helping those with Alzheimer’s, and with fewer side effects.”
Doctors are now seeking eligible participants for the T2 Protect AD study. To enroll in T2 Protect AD, participants must be between age 50 and 85, diagnosed with mild to moderate Alzheimer’s disease, and already being treated with Alzheimer’s medications for at least three months. Participants must have a study partner who has regular contact with the clinical trial candidate and is able to attend study visits.
Troriluzole is a prodrug of riluzole, a drug first approved by the Food and Drug Administration in 1995 to slightly slow disease progression in patients with Amyotrophic Lateral Sclerosis (ALS).
A prodrug is an inactive medication that changes into a drug after ingestion. When a person takes troriluzole, the body converts it into the active drug riluzole. This means the prodrug troriluzole can be taken once a day, while riluzole is administered twice a day. Unlike riluzole, patients do not need to fast before and after taking troriluzole, and troriluzole has potential for better safety and tolerability than riluzole.
The Miller School is one of more than 30 sites in the U.S. participating in the T2 Protect AD study. The study is sponsored by New Haven-based Biohaven Pharmaceutical Holding Company Ltd., and is coordinated by the Alzheimer’s Disease Cooperative Study, a large clinical research consortium based at the University of California, San Diego.
The T2 Protect AD trial comes at a time when Alzheimer’s research is focused on earlier stages of the disease and there are not as many clinical trials for people already diagnosed with Alzheimer’s. “Simply put, we need to identify more and better treatments for the millions of people already diagnosed with Alzheimer’s disease, and the T2 Protect Study is designed for that population,” said Dr. Baumel.
For more information about participating in the T2 Protect AD study at the University of Miami, call (305) 243-0184 or visit T2 Protect AD.
Written by Kai Hill.